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Immunopathological evidence suggests that activation of the alternative pathway of complement 
(AP) is involved in membranoproliferative glomerulonephritis (MPGN) and in immunoglobulin 
A nephropathy.  In this report we describe an AP dysfunction-associated factor that was isolated 
from the serum and urine of a patient with hypocomplementemic  MPGN. Extensive glomerular 
deposits of C3,  properdin,  and of the terminal complement components were observed in the 
kidney of the patient. In her serum the AP hemolytic activity was virtually absent. When mixed 
with fresh normal serum, the patient's  serum induced a 96% C3 conversion during a 30-min 
incubation  at  +37~  This  activity was  found  to  be  due  to  a  circulating  factor  that  by 
immunochemical characterization proved to be a 46-kD monoclonal immunoglobulin X light 
(L) chain dimer (~L)- Purified ~,r, but not control ~, or Ic L chains from patients with L chain 
disease, activated the AP in a dose- and ionic strength-dependent manner. Functionally, XL was 
differentiated from C3 nephritic factor (an autoantibody against the AP C3 convertase, C3bBb) 
by its inability to bind to and stabilize the C3bBb enzyme. Instead, Jkr was observed to interact 
directly with the AP control factor H. Thus, hL represents a novel type of immunoglobulin- 
related AP-activating factor with the capacity to initiate alternative complement pathway activation 
in the fluid phase. 
T 
he alternative pathway of complement (AP)  1 is consid- 
ered to play a crucial role in protection against infec- 
tious diseases (1, 2). It promotes phagocytosis and can cause 
cytolysis of microbes, virus-infected cells, and some tumor 
cells. Target structures for the AP are usually recognized in 
a discrimination  process, which involves downregulation of 
an interaction between target-associated C3b molecules and 
control factor H  (3-5). 
An association between AP activation/dysfunction and 
human glomerulonephritis has been observed in several  studies 
(6-8). The involvement of the AP in kidney disease has been 
judged from immunofluorescence analysis of kidney biopsy 
specimens (deposition  of complement components in glo- 
meruli) and from changes in total serum complement activity 
I Abbreviations used in this ~per: AP, alternative pathway of complement; 
C3 Nef, C3  nephritic factor; EM,  electron microscopy; IFL, immu- 
nofluorescence; IFX, immunofixation; LM, light microscopy; MPGN, 
membranoproliferative glomerulonephritis; NHS, normal human serum; 
P, properdin. 
or in levels of individual components.  In one subset of glo- 
merulonephritis,  membranoproliferative glomerulonephritis 
(MPGN) type II, characterized by intramembranous dense 
deposits in glomerular basement  membranes,  the AP dys- 
function has been shown to be due to an abnormal autoanti- 
body in patient sera. This IgG antibody, C3 nephritic factor 
(C3 Net'), reacts with and stabilizes the newly assembled AP 
C3 convertase, C3bBb (9-11). Stabilization of C3bBb by C3 
Nef causes its increased resistance to spontaneous or factor 
H-mediated decay dissociation resulting in prolonged sur- 
vival of the enzyme (12, 13) and in an accelerated turnover 
of C3,  which is the substrate for the C3bBb  enzyme. 
In this report we describe a novel type of factor, an Ig ~, 
L chain dimer (XL), with a capacity to initiate activation of 
the alternative pathway in the fluid phase. This factor was 
isolated from the serum and urine of a patient with hypocom- 
plementemic MPGN.  Studies of ~,g have revealed a previ- 
ously unrecognized interaction between an lg fragment and 
the alternative pathway activation system. 
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Case History and Patient Samples.  The patient (AL), a 57-yr-old 
Caucasian woman with no history of serious illness, presented with 
weight loss (10 kg/mo), anemia (hemoglobin level, 95 g/liter), and 
renal insufficiency, as indicated by increased serum creatinine  (up 
to 1,200/~mol/liter, normal range 70-106  #tool/liter) and urea 
(up to 40 mmol/liter, normal range,  2.3-6.5 retool/liter) levels. 
1 mo before, she had suffered from upper respiratory and gastroin- 
testinal  tract infections  of unknown cause. Analysis of the urine 
showed microscopic hematuria and proteinuria (4.2 g/liter). Pro- 
teins in the urine contained originally 0.78 g/liter of free Ig X L 
chains (and <0.05 g/liter of K L chains), as studied by a polyeth- 
ylene glycol-enhanced radial immunodiffusion procedure  using 
mAbs specific for free human ~, L chains (The Binding Site, Bir- 
mingham, UK). lmmunofixation (IFX) analysis (see below) of the 
urine showed a monoclonal band reacting with polyclonal anti-X 
antiserum (Behringwerke, AG, Marburg, FRG). Protein electropho- 
resis of the patient serum revealed a weak extra band in the fll 
region. It could be immunofixed with antisera to ~, L chains, but 
not with antisera to r  L chains nor with antisera to 3',/~, c~, 8, 
or e H  chains. No evidence for multiple myeloma was obtained 
from histological analysis  of bone marrow biopsy specimens or from 
x-ray studies during a follow-up  period of 2 yr. 
Both serum and EDTA (0.01 M) plasma samples were taken from 
the patient on six occasions with an interval  of 1.3 yr between 
the first and last samples. Samples were stored in aliquots at -70~ 
before analysis. Plasmapheresis plasma and urine samples were also 
obtained and kept at  -20~  before ffactionation procedures.  A 
kidney sample was obtained by a percutaneous needle biopsy under 
ultrasound guidance.  Normal human sera (NHS) were obtained 
from healthy laboratory personnel. Serum from a patient with post- 
streptococcal  glomerulonephritis (PSGN) and sera from patients 
with L chain myelomas were obtained from the district of the 
University Central Hospital of Helsinki and stored  at  -20~ 
Microscopical  Studies.  The renal biopsy specimen was processed 
for light (LM), immunofluorescence (IFL), and electron microscopic 
(EM) study according to standard methods. For IFL microscopy, 
pieces of the biopsy were frozen in isopentane cooled with liquid 
nitrogen. Cryostat sections (5/~m) were fixed in 3.5%  parafor- 
maldehyde in PBS, pH 7.4,  for 10 rain and washed three times 
for 5 rain with PBS. The bound complement components or Igs 
were  detected by  incubating  the  sections  with  fluorochrome- 
conjugated (rabbit or goat) antisera to Clq, C4, C3c, IgG, IgA, 
or IgM (Behringwerke AG). Other complement components or 
Ig L chains were detected by first incubating the sections with un- 
labeled polyclonal (rabbit  or goat) antibodies  to C3d, P, H, C5, 
C6, C7, C8, C9 (Quidel Corp., San Diego, CA), r, or ~ L chains 
(Behringwerke AG), or with a mouse anti-iC3b neospecific mAb 
(Quidel Corp.),  followed by incubation with a second,  fluoro- 
chrome-conjugated  antibody  (goat  anti-rabbit  IgG  or  rabbit 
anti-goat IgG; Behringwerke AG). Sections were analyzed by using 
a standard microscope equipped with epi-illumination and inter- 
ference filters for fluorescein and rhodamine fluorescence (excita- 
tion filter BP 455-490, dichroic mirror FT510, emission filter LP 
520; Osram HBO 50W high pressure mercury lamp; Carl Zeiss, 
Inc., Thornwood, NY). For photography, Kodak Tri-X film was 
used. 
Purified Complement Proteins  and Preparation of Complement Inter- 
mediates.  Complement components C3, H, B, and D were purified 
according to procedures modified from earlier studies (5, 14, 15). 
The complement components used in the fluorimetric assay were 
purified at the Department of Biochemistry,  University of Texas 
Health Center (Tyler, TX) (5, 14, 16). Native, functionally active 
C3 was separated from inactive C3 by FPLC on a mono S column 
(Pharmacia, Uppsala, Sweden). Properdin was isolated as described 
(17, 18). Sheep erythrocytes bearing C3b (EC3b)  and the active 
AP C3 convertase (EC3bBb) were generated at + 30~  using C3, 
B, D,  and Ni  2§  in gelatin (0.1%)  veronal buffered saline (VBS) 
buffer, pH 7.4 (Ni-GVB;  4,  19). 
Hemolysis Tests for Complement Activity and Methods to Detect 
Cleavage of C3, C4, C5, and Factor  13.  Alternative pathway hemo- 
lytic activity was tested by hemolysis of  guinea pig or rabbit erythro- 
cytes,  and classical pathway hemolytic activity by hemolysis  of 
antibody-sensitized  sheep red cells using both tube hemolysis and 
hemolysis-in-gel  assays (20). Hemolytic tests for C3 Nef activity 
were according to Arnaout et al. (21). Antigenic levels of the in- 
dividual  AP components were determined by single  radial im- 
munodiffusion. 
C3 conversion to C3b/iC3b was analyzed by an IFX electropho- 
resis method as described before  (22).  The anaphylatoxins  C3a 
desArg (23), C4a desArg (24), and C5a desArg (23) were quanti- 
rated by an ILIA (Amersham International, Amersham, UK). The 
AP-activating capacity of whole sera, C3 conversion, and genera- 
tion of the anaphylatoxins were analyzed from mixtures of NHS 
and patient serum after a 30-rain incubation at + 37~  C3 activa- 
tion was analyzed both in PBS, pH 7.4, and in MgEGTA-PBS (0.005 
M  MgCI2, 0.01  M  EGTA in PBS). 0.01 M  EDTA (chelator  of 
both  Mg  ~+  and  Ca  z+)  was  used  as  a  control  to  block  both 
pathways of complement activation.  To test for AP activation by 
purified Ig L chains, these were added at varying concentrations, 
dissolved in VBS, pH 7.4, into fresh NHS, and C3 cleavage was 
studied by C3a RIA. 
Gradient  (8-20%)  SDS-PAGE was  performed  according  to 
Laemmli (25). For reduction of the samples, 2-ME was used. The 
molecular mass markers (Bio-Rad Laboratories,  Richmond, CA) 
used were hen egg white lysozyme (14.4 kD), soybean trypsin in- 
hibitor (21.5 kD), bovine carbonic anhydrase (31 kD), hen egg white 
OVA (42.7 kD), BSA (66.2 kD), and rabbit muscle phosphorylase 
b (97.4 kD). As a radioactive protein standard a 14C-methylated 
protein mixture (Amersham International) was used: lysozyme (14.3 
kD), carbonic  anhydrase (30 kD), OVA (46 kD), BSA (69 kD), 
phosphorylase b (92.5 kD), and myosin (200 kD). Electrotransfer 
and immunoblotting were according to Towbin et al. (26). Anal- 
yses of factor B and C5 conversion were done using nitrocellulose 
replicas from agarose and SDS-PAGE gels. The nitroceUulose sheets 
were stained with peroxidase-conjugated  specific antisera against 
factor B (rabbit polyclonal), Bb fragment (mouse monoclonal), or 
C5 (rabbit  polyclonal;  all antisera were from Quidel Corp.). 
Fractionation of Patient Serum.  Initially, 150/~1 of serum from 
patient AL was applied to a Superose 6 gd filtration column (Phar- 
macia) equilibrated with PBS, pH 7.4. Protein concentration was 
followed by measuring the absorbance at 277 nm. To determine 
the complement-activating capacity of the chromatography frac- 
tions, equal volumes of each fraction and NHS were mixed and 
incubated for 30 rain at + 37~  and the resultant C3 cleavage was 
analyzed by both the C3 conversion IFX and C3a generation assays. 
Fractions were also analyzed by nondenaturing protein electropho- 
resis. IgG, IgA, and IgM were quantitated by radial immunodiffusion 
against polyclonal antisera (Behringwerke  AG). The presence and 
monoclonality of free X L chains in chromatography fractions were 
assessed by Ouchterlony and IFX analysis, respectively. Free X L 
chains were quantitated by a combined densitometer scanning of 
the IFX gel and single  radial immunodiffusion using free X L 
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tiserum (Behringwerke AG) was tested by Ouchterlony double im- 
munodiffusion. 
Purification of the Complement-activating  Factor.  2 ml of the pa- 
tient serum was precipitated  with 40% ammonium sulphate  in PBS, 
pH 7.4. The supernatant was dialyzed overnight against 10 mM 
diaminopropane, 0.01 M HCI, pH 8.3, containing 0.025% NAN3, 
and applied to a mono Q anion exchange  column (Pharmacia). The 
column was eluted with a NaC1 gradient (0-0.5 M) at a flow rate 
of 600/zl/min. Fractions (1.8 ml) were tested for the presence of 
monoclonal and polyclonal Igs by Ouchterlony double diffusion 
using both anti-to  and anti-X antisera, the former precipitating only 
the polyclonal Igs. The ability of the fractions to activate comple- 
ment was tested after dialysis against PBS. 
The complement-activating  factor  was purified  from patient urine 
using a SI17 column (an anion exchange column; Pharmacia). 300 
ml of urine was dialyzed against 10 mM phosphate buffer, pH 7.4, 
and concentrated before application to the column. The column 
was run at a flow rate of 1 ml/min and proteins were eluted with 
a NaC1 gradient collecting 3-ml fractions. Protein concentration 
was followed by absorbance at 277 nm, and X L chains were de- 
tected by Ouchterlony double diffusion. 
Monoclonal X L chains from patient plasmapheresis plasma and 
control X (Xv, Xg) and tr (Kw) L chains from the sera and urines 
of patients with L chain myelomas  were isolated as described above 
for serum. Proteins were radiolabeled with 12sI using the Iodo- 
beads technique (Pierce Chemical Co., Rockford, IL) to specific 
activities of 0.5-1.0 #Ci/mg. 
Cation Exchange Chromatography of Patient Serum.  500/~1 of 
serum was applied to a CM-TSK column (Bio-Rad Laboratories) 
in 10 mM phosphate buffer, pH 6.2, (flow rate: 600/~I/min). Frac- 
tions were tested for the presence of X L chains by double im- 
munodiffusion and IFX analysis.  Positive  fractions were pooled and 
rechromatographed  on the same  column with a NaC1 gradient (con- 
ductivity from 8.5 to 44 millisiemens (mS  D in 25 mM phosphate 
buffer, pH 5.5. Superose 6 gel filtration was used as the final step 
to separate X L chains from albumin. 
Binding of ~L to Es-C3b and Es-C3bBh  The purified and radio- 
labeled hL or control X L chains (Xv, X~,) were added at varying 
concentrations (up to 60 #g/ml) to suspensions of Es, Es-C3b, or 
Es-C3bBb (6  x  108 cells/ml) in a final volume of 100 #1 gelatin 
veronal buffer (GVB) and incubated with stirring for 30 min at 
30~  Cell-bound radioactivity was determined after centrifuga- 
tion of the mixtures through 20% sucrose. The percentage of L 
chain binding was obtained by counting the radioactivity in pellets 
and supernatants. For hemagglutination experiments, polyclonal 
antisera against X L chains, C3c, and factor B {Behringwerke  AG) 
were used. Residual  C3 convertase  activity  was assayed  by incubating 
the cells  with normal rat serum diluted 1:15 in GVB-~  at 370C 
for 60 rain. Cell lysis was determined as hemoglobin release (ab- 
sorbance at 412 nm). 
Fluorescence Quenching Assay for  C3bBb Stabilizing Activity. 
Cleavage of C3 to C3b by the enzyme C3bBb was assayed  fluori- 
metrically essentially as described earlier (27, 28). C3bBb enzyme 
was preformed by mixing and incubating (2 rain at 220C) 22.5 
#g C3b (generated by trypsin), 96 #g factor B, 2.5/~1 50 mM 
MgCI2, and 0.8 #g factor D in a final volume of 60/zl of VBS. 
Formation of the enzyme was stopped by adding 60 #1 of ice-cold 
VBE (VBS with 0.04 M EDTA). 40/~1 of the enzyme was added 
immediately after its formation to cuvettes containing native C3 
(193 #g/ml), the fluorescent probe ANS (8-anilino-l-naphtalene 
sulphonate, 40/zM),  and either properdin (P; 40/~g/ml),  XL (71 
#g/ml), or a corresponding amount of HBS (20 mM Hepes, 140 
mM NaC1) buffer, pH 7.4. C3 cleavage was followed by a spec- 
trofluorometer (8000-C; SLM Instruments, Urbana, IL) with ex- 
citation and emission  wavelengths  of  386 and 472 nm, respectively. 
Binding of At  to Factor H.  Flexible microtiter  plate wells 
(Linbro; Flow Laboratories, Inc., Hamden, CT) were coated (over- 
night at  +4~  with factor H, C3b, or BSA (all at 10 #g/ml) 
in VBS. After blocking of unbound binding sites with 0.1% gelatin 
in VBS-Tween  20, 0.1% (3/BS-T), the plates were thoroughly washed 
with VBS-T, and dilutions of radiolabeled XL L chains (1.5  x  106 
cpm/#g) were added to microtiter plate wells in duplicate and in- 
cubated for I h at room temperature. After removal of the radiola- 
beled proteins, the plates were washed four times with VBS-T and 
individual wells cut out and counted in a gamma counter. 
Sucrose Density Gradient Analysis.  IzSI-labeled  hL (final concen- 
tration, 0.45 ttg/ml) was incubated  (30 rain at +37~  with purified 
factor H (0.75 mg/ml), BSA (2 rag/m1), or with NHS (diluted 
1:2), and layered  on top of 10--30% sucrose  gradients in PBS. Gra- 
dient tubes were centrifuged for 18 h at 40,000 rpm using a SWS0 
rotor in an ultracentrifuge (b70; Beckman Instruments Inc., Palo 
Alto, CA). Fractions (140/~1) were collected from the bottom of 
the tubes and counted for radioactivity. Hb, BSA, IgG, and IgM 
were used as migration markers. 
Results 
Glomerular Lesion: LM, EM, and IFL Microscopic Findings. 
The kidney biopsy specimen of the patient was studied by 
routine histological and immunohistological methods. By LM, 
all  (•15)  glomerular capillary tufts in the specimen were 
moderately condensed due to an increase in the mesangial 
matrix, thickening of the capillary wails, and slight prolifer- 
ation of mesangial and endothelial calls. In silver staining, 
the  peripheral  capillary  glomerular  basement  membrane 
(GBM) appeared "duplicated" (Fig. 1 A), suggesting mesan- 
gial interposition or intramembranous deposits. The tubules 
were atrophied, and the interstitium was heavily fibrotic and 
infiltrated by round cells. One small artery showed destruc- 
tion of the vessel wall with infiltration of round cells, i.e., 
vasculitis. 
Two glomeruli were studied by EM. In both, '~50% of 
the capillary loops contained intramembranous-subendothelial 
deposits  of moderate electron density (Fig.  1 B).  Similar 
deposits were present in the mesangial matrix. Some capil- 
laries  showed circumferential mesangial interposition.  No 
deposits were detected in Bowman's capsule or tubular base- 
ment membranes. 
By IFL, intensive coarse granular deposits of C3 were de- 
tected along the capillary walls and in the mesangial regions 
(Fig. 2), when stained with antisera (anti-C3c), that recog- 
nize C3, C3b, iC3b, and C3c. There was similar, but weaker, 
staining when anti-iC3b-neoantigen  antiserum was used. Anti- 
C3dg antisera showed an extensive linear staining along cap- 
illary basement membranes. Properdin (Fig. 3 A) and the mem- 
brane attack complex components C5 (Fig.  3 B), C7, and 
C9 were present as deposits similar to those of C3, although 
the staining reactions with the respective antisera were slightly 
weaker.  The alternative pathway control factor H  was also 
found deposited in the kidney glomeruli (Fig. 3 C). Factor 
H  depositions were less intense than those of C3 and they 
appeared in a diffuse linear fashion along the basement mem- 
941  Meri eta]. Figure 1.  (/1) LM (silver stain) and (B) EM appearance 
of the patient kidney biopsy specimen. An increase in the 
mesangial matrix and and thickening of the capillary walls 
are evident. At several sites (A), the glomerular basement 
membrane appears duplicated apparently because of dense 
intramembranous-subendothdial deposits (/3) in the cap- 
illary loops. The pattern corresponds  to an atypical form 
of MPGN with features of both types I (subendothelial 
deposits)  and II (dense intramembranous deposits). 
Figure 2.  IFL microscopy demon- 
stration of intense C3  deposits in  a 
glomerulus  and  in  an  artery  wall. 
Unfixed cryostat section of the biopsy 
specimen  was  labeled with  a  FITC- 
labded antiserum against C3c (x 650). 
942  Activation of the Alternative Pathway  of Complement by X Light Chains Figure 3.  lmmunofluorescence  mi- 
croscopy  detection  of  (A) properdin,  (B) 
C5, and (C) factor  H in glomeruli.  (D) 
Staining  for IgG does  not show  glomer- 
ular deposits (x 200). 
branes and not as coarse granular deposits.  No deposits of 
Clq,  C4,  or Igs (with H  chain-specific antisera) were de- 
tected. Ig )x, but not K, L chains were occasionally seen de- 
posited in damaged glomeruli and as tubular casts (Fig.  4). 
In some glomeruli, X L chains appeared faintly along the base- 
ment membranes similarly as factor H. 
Complement Activity and Igs in Serum.  The tube hemol- 
ysis titration and the hemolysis-in-gel (hemolysis of guinea 
pig or rabbit erythrocytes) analysis of the fresh patient serum 
showed  a  markedly  decreased  AP  hemolytic  C  activity 
(<20%, compared with a pool of normal control sera), but 
the classical pathway hemolytic activity was at the normal 
level (75 IU/ml; cut off level, 60 IU/ml).  Levels of the in- 
dividual alternative pathway C  components, as determined 
by single radial immunodiffusion, were low, but detectable: 
C3,  0.07 g/liter (normal range, 0.6-1.4  g/liter);  factor B, 
0.06  g/liter  (0.1-0.4  g/liter).  Factor  H  (122%),  factor  I 
(138%), and C4 (0.39 g/liter, 0.2-0.6 g/liter) were present 
at normal antigenic levels  in the patient serum. Antisera against 
properdin gave only a weak precipitin band in an Ouchter- 
lony double diffusion test. The IgG, IgA, and IgM concen- 
trations in serum were within normal range (not shown). 
No rheumatoid factors or cryoglobulins were detected, and 
IFLtests for antiglomerular and antitubular basement mem- 
brane antibodies in  serum were negative. 
Detection of  a Complement-activating  Factor in Serum.  The 
low levels of C3 and B, but not of C4, in patient serum sug- 
gested the presence of  C3 nephritic factor. A nearly total (96%) 
C3 conversion was obtained after mixing and incubating (30 
min at  +37~  the patient serum with fresh NHS (Fig.  5). 
Figure 4.  IFL detection  of  ~ L chains 
in patient kidney. S L chains can be 
found (A) deposited  in damaged  glo- 
meruli or (B) as tubular casts (x 400). 
943  Meri et al. Figure 5.  Demonstration of (A) C3 and (B) factor B cleavage in NHS 
by patient serum. NHS alone (lane I), NHS with zymosan, I mg/ml (lane 
2), or a mixture of patient serum and NHS (1:1) (lane 3) were incubated 
for 30 rain at +37~  and subjected  to electrophoresis  in agarose. C3 cleavage 
was studied by IFX with a polyclonal anti-C3c antiserum. Activation of 
factor B was analyzed by immunoblotting using a monodonal anti-Bb 
antiserum on a nitrocellulose replica of an agarose gel. Note the some- 
what different C3 cleavage  patterns induced by zymosan and patient serum: 
a virtually complete and homogenous  cleavage of C3 is induced by the 
patient serum. 
This C3 conversion was inhibited with 0.01 M EDTA but 
not with 0.01 M MgEGTA (5 mM MgC12; Table 1). Factor 
B (Fig. 5) and C5 (CSa desArg formation) were also cleaved, 
but not C4 (C4a desArg), which shows that activation oc- 
curred through the alternative pathway (Table 1). NHS was 
depleted of alternative pathway hemolytic activity when mixed 
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Figure 6.  Comigration of C3 cleaving activity with monoclonal ~, L 
chains in gel filtration analysis of patient serum. 150 ~1 of patient serum 
was fractionated on a Superose 6 column. Protein concentration was fol- 
lowed by absorbance at 277 nm. Complement-activating  capacity of the 
chromatography fractions was tested by the C3 conversion IFX and C3a 
generation assays. The presence and monoclonality  of free )~ L chains in 
chromatography fractions were assessed  by the immunodiffusion  and IFX 
analysis, respectively. Levels  of IgG and free ), L chains were quantitated 
by single radial immunodiffusion using monospecific  antisera and by quan- 
titative densitometer scanning of IFX gels. Results are expressed as per- 
cent of total input (1.8 mg of IgG and 105/zg of )~ L chains). 
with patient serum at a ratio of 1:1 and incubated for 30 min 
at  +37~  It is thus apparent that the patient serum con- 
tains some factor(s) capable of activating the AP in serum. 
The activity persisted in the patient serum during a follow- 
up period of 1.3 yr, as shown by analyzing five samples taken 
Table  1.  Alternative  Pathway Activation  by Gloraerulonephritis Patient Sera 
Complement activation fragment generation* 
Sample mixture#  C3a  C3b/bi  C4a  C5a 
/~g/ml  %  /~g/ml  ng/ml 
NHSI + NHS2 + EDTA  1.2  0  0,35  <10 
+ PBS  3.9  3  0,88  15 
+ MgEGTA  4.7  6  0.94  18 
NHS1 + PSGN  serum + EDTA  1.2  14  1.1  <10 
+ PBS  3.8  29  1.2  <10 
+ MgEGTA  3.0  31  1.3  14 
NHSi + serum L + EDTA  2.5  10  0.80  <10 
+ PBS  18.2  91  0.82  48 
+ MgEGTA  27.0  95  1.2  32 
* Anaphylatoxin levels were determined by a RIA and C3 conversion (C3b/bi percent) by an electrophoresis immunofixation  assay as described in 
Materials and Methods.  Values represent  means of duplicate measurements. 
* NHS and patient sera (serum from a patient with poststreptococcal glomerulonephritis  or serum from patient L with MPGN) were mixed in the 
presence of EDTA (10 mM), buffer, or MgEGTA (5 mM MgC12; 10 mM EGTA) and incubated for 30 rain at + 37~  before C activation fragment 
determination. 
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Figure 7.  Purification of the complement-activating factor (XL) from 
patient serum (A) and urine (B) by anion-exchange chromatography. (A) 
Patient serum (150/~1) was applied to a Mono Q (Pharmacia) column in 
10 mM diaminopropane, pH 8.3, containing  0.025% azide. Absorbance 
was monitored at 277 nm, and )~ L chains were detected and quantitated 
as in Fig. 6. Purity of Xt was analyzed by immunoelectrophoresis, SDS- 
PAGE, and immunoblotting  assays. Functional activity was tested by de- 
termining the production of C3a in NHS either before (O) or after (O) 
dialysis against PBS. (B) Concentrated urine in 10 mM phosphate buffer 
was applied to a SI17 column as described in Materials and Methods. The 
monoclonal )~ L chains bound strongly to the column and became eluted 
as two separate peaks (I and II). 
during this period. Similar activity was also detected in samples 
of patient urine that was tested after pH adjustment to 7.4. 
Purification and Properties of the Complement-activating Factor. 
When patient serum was subjected to gel filtration on a Su- 
perose 6 column in PBS, pH 7.4, the AP-activating factor 
was observed to elute after the IgG peak, as followed by a 
C3 conversion IFX assay and by C3a desArg RIA (Fig. 6). 
Electrophoretic analysis of the complement-activating frac- 
tions showed an atypical protein band between the c~2 and 
/31 fractions.  IFX analysis using antisera  specific for Ig % 
/~, o~, or ~ H chains, Fd-piece, and K and X L chains showed 
that this band reacted with the anti-S L chain antiserum but 
not with the other antisera.  Homogeneity of the anti-h- 
reactive band suggested that it is a monodonal S L chain. 
Quantitative analysis of free X L chains in the gel filtration 
fractions indicated that they comigrated with the AP-activating 
activity (Fig.  6). 
To test whether the monoclonal component induced C 
activation, the X L chains were purified from patient serum 
as well as from plasmapheresis plasma and urine. In Mono 
Q anion exchange chromatography (Fig. 7 A), free S L chains 
were found to elute as a distinct homogenous peak at a salt 
concentration of 0.350 M. In the presence of 0.350 M NaCI, 
the S L chain-containing fractions induced only a moderate 
C3 activation response as measured by C3a desArg forma- 
tion, and the level of spontaneous C3 conversion in the pres- 
ence of the other fractions appeared to be inversely propor- 
tional to the salt concentration in the fractions. When assayed 
after dialysis against PBS, pH 7.4, the S L chains induced 
an extensive complement activation in NHS (C3a levels up 
to 22/~g/ml), whereas the other fractions did not (C3a levels 
<3 #g/ml). The activation occurred in the presence MgEGTA 
(0.01 M) indicating the AP as the activation route. 
SDS-PAGE of the S L chain-containing fractions (Fig. 8 
A, lane 1, and B, lane 4) showed a homogenous protein, 
which under reducing conditions (Fig. 8 C) migrated as a 
single band of '~23 kD. Ouchterlony double diffusion, im- 
munoelectrophoresis, and immunoblotting  analyses confirmed 
that the protein was an Ig S L chain. For this reason,  the 
factor was  named as  Sr  (L being derived from patient's 
family name). Protein electrophoresis showed that the iso- 
lated SL was a monoclonal protein migrating between the 
oL2 and 81 fractions similarly to the monodonal band in pa- 
tient serum and urine. The concentration of free S L chains 
was "~0.7 mg/ml in the patient senma. Immunoblotting  anal- 
ysis (Fig. 8 B) showed that St was present both as a dimer 
and monomer (in an approximate ratio of 4-5:1) in patient 
serum and urine. 
During purification of St from urine (Fig. 7 B) two ho- 
mogeneous peaks (I and II) reacting with S L chain antisera 
were obtained. On SDS-PAGE under nonreducing conditions 
(Fig. 8 A) the 23-kD form was preferentially  seen in peak 
I (lane 2), and the 46-kD form in peak II (lane 3), although 
the two forms were present in both peaks. 
In  cation  exchange chromatography using  a  CM-TSK 
column, SL showed an elution pattern distinct from that of 
IgG (not shown). While Igs bound to this column, the mono- 
clonal X L chains eluted in the breakthrough fractions in 10 
mM phosphate buffer, pH 6.5.  St bound to the CM-TSK 
column in 25 mM phosphate buffer, pH 5.0-5.5,  and elu- 
tion was achieved using a salt gradient (8.5-44 mS). Superose 
6 gel filtration was used as the final step to allow separation 
from albumin. C3 cleaving activity was again observed to 
comigrate with the Xr L chains. 
Activation of the Alternative Pathway by At.  The purified 
SL activated the alternative  complement pathway in fresh 
NHS  (Fig.  9, A  and B).  Activation was dose dependent, 
saturable,  and sensitive to ionic strength (Fig. 9, C and D). 
As with whole serum, activation by the purified Xr resulted 
in cleavage of C3, factor B, and C5, but not of C4. Control 
L chains (isolated  from patients with L chain myelomas), 
whether of S or K subtype, failed to activate the alternative 
pathway (Fig.  10). 
/~L Does Not Stabilize the Alternative Pathway C3 Conver- 
tas~  Purified C components were used for studying whether 
945  Meriet al. Figure 8.  SDS-PAGE  of XL purl- 
fled from serum and urine and im- 
munoblotting analysis of patient 
serum  and urine. (.4) Samples of 
serum XL (lane I,  see Fig. 6 A), 
and urinary XL (pooled peaks I and 
II, lanes 2 and 3, respectively; see 
Fig. 6 B) were run in a 12% SDS- 
PAGE get under nonredudng  con- 
ditions. Molecular mass markers are 
shown on the right. Note the higher 
relative amount of ~, L chain mono- 
mers in peak I sample of the uri- 
nary XL. (B) Western blot analysis 
of patient serum  and urine using 
anti X-antiserum. Samples of NHS 
(lane 1), patient serum (lane 2), and 
urine (lane 3)  were  run in SDS- 
PAGE (8-12% gradient gel) under 
nonreducing  conditions. The sepa- 
rated proteins were transferred onto 
nitrocellulose  and  stained  with 
peroxidase-conjugated anti-human 
X antibodies. Purified radiolabeled 
Xt was run as a control (lane 4). In 
patient  serum,  kt  appears prin- 
cipally as a dimer and monomer, although a trace of a tetramer  (X4) is also present.  The broad high molecular mass bands represent X L chains of 
whole Igs of different isotypes. In urine, both dimers and monomers are seen. (C) SDS-PAGE of purified radiolabeled XL under reducing conditions. 
14C-methylated protein standard mixture is shown on the right. 
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Figure  9.  Time  course,  dose-re- 
sponse, and ionic strength effects on al- 
ternative  pathway  activation  by  XL. 
Activation-associated  cleavage  of (A) C3 
and (B) C5,  respectively. Purified ~g 
(0.3 mg/ml, final concentration) (e) or 
buffer (O) were added to NHS and in- 
cubated at +37~  Generation of C3a 
and C5a was quantitated by RIA. (C) 
For estimating the dose-response  effect, 
increasing concentrations  of XL (in 50 
/.tl of VBS, pH 7.4) were added to 150- 
#1 aliquots of NHS and incubated at 
+ 37~  for 30 min before quantitating 
C3a.  (D) The effect of ionic strength 
on the alternative  pathway activation re- 
sponse by ~.t- 100 ~1 ~.L (0.3 mg/ml, 
final) (0)  or buffer  (O) were mixed 
with NHS (150 #1) and varying con- 
centrations of NaCI (0-1.0 M NaC1 in 
150 #1), and incubated at  +37~  for 
30 min before quantitating C3a. 
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Figure 10.  Complement activation by )~t in comparison with control 
L chains. ~,t or control L chains (kv, Kw) purified from urines of patients 
with L chain myelomas were incubated at 0.1 rag/m] in NHS for 30 min 
(+37~  in the presence of EDTA (10 mM), PBS, or MgEGTA (5 mM 
MgClz,  10 mM EGTA).  C3a was quantitated by RIA. C3a formation 
in the absence of L chains was taken as background and has been sub- 
tracted from the values shown. 
XL binds to, and stabilizes, the AP C3 convertase, C3bBb. 
Properdin was used as a control stabilizing factor. The C3bBb 
enzyme was assembled on sheep erythrocytes (E~). When 
3.0 #g of either t2sI-Xt or control ~, L chains (t2sI-)w) were 
mixed with 6  x  107 ErC3bBb cells (bearing "o30,000 C3b 
molecules/particle)  and incubated  for 30 min at  +37~ 
,ol.0%  (kr)  and 0.95%  (kv) of L  chains  were detected 
bound after centrifugation through 20% sucrose.  This binding 
did not differ significantly from binding to E, cells alone or 
to EcC3b.  No hemagglutination of Xr-treated  ErC3bBb 
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Figure 11.  Lack of C3bBb-stabilizing effect of)~z, as demonstrated by 
a fluorescence quenching assay of C3 cleavage. Preformed C3bBb enzyme 
(see Materials and Methods) was added to cuvettes containing native C3 
(1.0 #M), the fluorescent probe ANS (8-anilino-l-naphtalene sulphonate, 
40 #M), and P (0.18 #M), )~L (X, 1.5 #M), or buffer (control). Follow- 
up of the resulting C3 cleavage to C3b shows the C3bBb stabilizing effect 
of properdin (highly accelerated C3 cleavage rate). XL does not show any 
significant  C3bBb-stabilizing effect. 
cells was observed when they were mixed with polyclonal 
antiserum against X L chains. Hemagglutination  was positive, 
when the same cells were mixed with either anti-C3  (anti- 
C3c) or anti-factor B antiserum. After adding normal rat serum 
(1/15) in GVB-EDTA, no difference between the residual C3 
convertase activity was  observed  between )~L-treated and 
control L chain-treated E,-C3bBb. As shown in Fig. 11, XL 
did not stabilize the C3bBb enzyme when present at a higher 
than equimolar concentration to C3b. Thus, the mechanism 
of alternative pathway activation by XL is distinct  from C3 
nephritic factor activity. 
Binding of Az. to Factor H.  To see if the activity of St 
could be due to its interaction with the AP control factor 
H, a direct binding experiment was performed. As shown 
in Fig. 12 A, radiolabeled XL bound to microtiter plate-fixed 
H, whereas no binding to C3b or BSA occurred. To see if 
XL is capable of forming fluid phase complexes with factor 
H, sucrose density gradient ultracentrifugation analyses  were 
carried out. Preincubation  of 12sI-XL with unlabeled factor 
H  (or with NHS) resulted in the appearance of a new XL- 
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Figure 12.  Binding of ~kL to factor H. (.4) Increasing amounts of ra- 
diohbded )~t were allowed to bind to microtiter plate-fixed factor H  (O), 
C3b (O) or BSA (R)- Each point represents a mean of triplicate determi- 
nations. (B) Sucrose density gradient (10-30%) ultracentrifugation profile 
of mI-~kt (final concentration,  10 -s M) preincubated with unlabeled factor 
H (Q) (5.0  x  10-6 M) or BSA (O) (3.0  x  10 -5 M) in PBS. Complexes 
of 12SI-)~L with factor H  correspond to a position of 7S. 
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complexes (Fig. 12 B). Similar complexes were observed when 
12SI-H (0.7  x  10 -s M) was added to patient serum. Regard- 
less of the relative amounts of )tL and H  in the preincuba- 
tion mixtures, the complexes migrated at a position corre- 
sponding to that of IgG (7S). This suggests that complex 
formation occurred primarily at an approximately 1:1 molar 
ratio.  The 1:1 ratio was confirmed in sandwich binding ex- 
periments where neither of the two components (),r or H) 
was capable of interacting simultaneously with solid phase 
and fluid phase ligands (not shown). 
Discussion 
This report describes the detection of a novel type of alter- 
native complement pathway-activating factor, a monodonal 
), L chain dimer, in human disease. The patient in whom 
the factor ()~L) was found suffered from an atypical form of 
glomerulonephritis. The electron microscopic findings (dense 
intramembranous deposits; Fig. 1) resembled those observed 
in MPGN type II, the form of glomerulonephritis associated 
with the presence of C3 nephritic factor (C3 Nef). In addi- 
tion to the characteristic  intramembranous dense deposits, 
lesions were observed in subendothelial spaces suggesting that 
the glomerulonephritis in our patient was of an intermediate 
type between MPGN I and MPGN II. 
Extensive deposition of C3, properdin, and of the terminal 
component components in glomeruli were seen in the kidney 
biopsy (Figs. 2 and 3). No deposits of Igs nor of the classical 
pathway components were detected. This pattern of C com- 
ponent deposition suggests that alternative pathway comple- 
ment activation has occurred in vivo. A similar C deposition 
pattern has been observed in other forms of glomerulone- 
phritis, such as in IgA nephropathy (29, 30). In the case of 
C3 Nef-associated glomerulonephritis, deposition of Igs in 
kidneys is also rare. Somewhat surprisingly, only small amounts 
of )x L chains were found deposited in the kidneys. The dis- 
tribution pattern of)~ L chains (Fig. 4) did not resemble that 
of C3, properdin, or C5b-9, but was similar to that usually 
observed in L chain disease (tubular casts and weak staining 
in glomerular basement membranes). The glomerular base- 
ment membrane deposition of X L chains was  somewhat 
similar to that of the alternative  pathway control factor H, 
which appeared in a linear fashion along the basement mem- 
branes rather than as coarse deposits (Fig. 3 C). These obser- 
vations,  together with  the  demonstration of an  efficient 
complement-activating capacity in the patient serum (Fig. 
5 and Table 1), indicate that AP activation has been initiated 
in the fluid phase and not at the sites of "activator" deposi- 
tion. It is likely that C3b, after its formation in the fluid 
phase, has become randomly attached to glomerular and vas- 
cular endothelial cell membranes with consequent deposition 
of further C components. The similar patterns of C compo- 
nent deposition and uhrastructural changes in our patient 
and in MPGN type II with C3 Nef suggest that the patho- 
logical changes in glomeruli predominantly result from AP 
activation instead of being directly caused by the abnormal Igs. 
Initially, the complement-activating  capacity in the patient 
serum was suspected to be due to C3 nephritic factor until 
it was observed that in gel filtration (Fig. 6) and in anion 
exchange chromatography (Fig. 7 A) the activity comigrated 
with free )x L chains. Subsequent purification of the comple- 
ment-activating factor (Fig. 7) and demonstration of its reac- 
tivity with anti-human )x L chain antisera further indicated 
its relationship to ~, L chains. The AP-activating factor did 
not react with anti-Fd antiserum, nor with anti-~ or anti-H 
chain antisera. The homogeneous appearance of the k L chains 
in agarose electrophoresis and in immunofixation  demonstrated 
their monodonality. Analysis of the activating factor by SDS- 
PAGE suggested that it is a dimer composed of two mono- 
clonal, and probably identical, disulphide-linked  23-kD poly- 
peptides. These results establish the AP-activating factor as 
a monoclonal k  L chain dimer (kL). 
Immunoblotting and immunofixation experiments with 
anti-k L chain antisera (Fig. 8) demonstrated that )~ dimers 
and monomers were the principal monoclonal components 
in patient serum and urine. There was no evidence for the 
presence of a circulating "parent" full size Ig carrying mono- 
clonal k  L chains in patient blood. During a follow-up of 
2 yr, the patient showed no evidence of developing myeloma. 
In contrast, the levels of monoclonal k  L chains gradually 
declined in her blood and reappeared only slowly after repeated 
plasmapheresis.  Thus, kL is probably the product of a be- 
nign clone of plasma cells producing X L chains. 
The isolated kL showed similar C activation kinetics as 
the whole patient serum, and activation of C by either pa- 
tient serum or purified )xt resulted in cleavage of C3, factor 
B, and C5, but not of C4. The small molecular mass dis- 
criminates kL from C3 Nef, which in most cases has been 
shown to be IgG (9, 10). The fact that )XL differs from IgG 
in molecular composition does not exclude the possibility 
that kr would act similarly as C3 Nef in activating the AP, 
i.e., by stabilizing the AP C3 convertase, C3bBb. This possi- 
bility was tested by both conventional C3bBb binding and 
stabilization experiments and by a novel fluorimetric test (Fig. 
11; reference 28).  The validity of the fluorometric test for 
C3bBb stabilization  was confirmed by using P as a positive 
control. The results  indicated that )XL did not bind to or 
stabilize  the  alternative  pathway  C3  convertase  enzyme, 
C3bBb. Thus, in addition to molecular properties, kr and 
C3 Nef differ from each other also by functional criteria. 
Some of the early descriptions of C3 Nef were controver- 
sial as to its immunochemical nature (e.g.,  reference 31). 
Bartlow et al. (32) have described a case of non-Ig C3-activating 
factor in MPGN, although the exact nature of the factor re- 
mained unsolved. In light of the present study, this factor 
could functionally be distinct from C3  Nef and perhaps 
resemble )~t in its mechanism of action. Without sensitive 
techniques for detection of monoclonal proteins, )~L-like fac- 
tors are easily missed. 
The lack of C3bBb-stabilizing effect of )xr indicates that 
other mechanism(s) for AP activation by circulating serum 
factors, especially  in association with glomerulonephritis, exist. 
A clue to the mechanism of action of kL was provided by 
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appeared to occur at a molar 1:1 ratio as both the 12sI-hr-H 
(Fig.  12 B) and 12SI-H-ht complexes migrated at a position 
of 7S. As it has been observed that L chain dimers derived 
from IgGl-dass Igs (anti-Mcg) may retain approximately the 
same binding properties as the whole parent molecules (33), 
it is possible that  Xr has an antigen-binding  site via which 
it reacts with factor H. Activation of the AP results if Xr, 
via this direct antibody activity or by other physicochemical 
means, blocks the activity of the AP control factor H, which 
under normal  conditions functions  as a negative regulator 
of the AP activation system. A functionally similar situation 
would be expected to occur in cases of inherited deficiency 
of factor H. A report by Levy et al. (34) described factor H 
deficiency in two brothers. Both of the patients suffered from 
glomerulonephritis,  which  ultrastructurally  and  immuno- 
histochemically showed a striking resemblance to our patient. 
Thus, the absence or functional neutralization of the alterna- 
tive pathway control factor H, by allowing increased alterna- 
tive pathway turnover in the fluid phase, appears to predis- 
pose to the development of glomerulonephritis. 
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